Capital Advisors Inc. OK Sells 1,709 Shares of Novo Nordisk A/S (NYSE:NVO)

Capital Advisors Inc. OK lessened its holdings in Novo Nordisk A/S (NYSE:NVO) by 2.6% during the 4th quarter, HoldingsChannel reports. The firm owned 65,183 shares of the company’s stock after selling 1,709 shares during the period. Capital Advisors Inc. OK’s holdings in Novo Nordisk A/S were worth $5,607,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the business. Daiwa Securities Group Inc. bought a new position in Novo Nordisk A/S during the third quarter valued at $28,000. Capital Performance Advisors LLP purchased a new stake in Novo Nordisk A/S in the third quarter worth about $42,000. Albion Financial Group UT lifted its position in shares of Novo Nordisk A/S by 121.4% during the fourth quarter. Albion Financial Group UT now owns 507 shares of the company’s stock valued at $44,000 after buying an additional 278 shares during the last quarter. Sound Income Strategies LLC lifted its position in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company’s stock valued at $46,000 after buying an additional 243 shares during the last quarter. Finally, Hager Investment Management Services LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at about $46,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.2 %

Shares of NVO stock opened at $83.78 on Wednesday. The stock’s fifty day moving average is $90.96 and its two-hundred day moving average is $110.91. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.75 and a current ratio of 0.74. The firm has a market capitalization of $375.95 billion, a P/E ratio of 25.46, a PEG ratio of 0.96 and a beta of 0.45. Novo Nordisk A/S has a fifty-two week low of $78.17 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Research analysts expect that Novo Nordisk A/S will post 3.86 earnings per share for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The company also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be issued a $0.7874 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 21.88%.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on NVO shares. BMO Capital Markets cut their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.